Mustang Bio inks agreement with Netherlands' Leiden University

By The Science Advisory Board staff writers

November 10, 2021 -- Mustang Bio has entered into an exclusive licensing agreement with Leiden University Medical Center in Leiden, the Netherlands, for an ex vivo lentiviral gene therapy for the treatment of recombination activating 1 severe combined immunodeficiency.

The therapy is being assessed in a phase I/II European clinical trial. Mustang Bio is working with Frank Staal, PhD, whose laboratory at the university developed the therapy, the company said. Staal will continue to develop other lentiviral gene therapies, and Mustang Bio will have licensing rights to them as well.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.